Phase 3 Clinical Trials With Primary Completion Dates in May 2018

This is a list of Phase 3 trials with primary completion dates in May 2018 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

SymbolCompanyPrimary Completion DatePhaseNCT IDTitle
ALKSAlkermes plc2018-05-01Phase 3NCT02110264Injectable Pharmacotherapy for Opioid Use Disorders (IPOD)
FGENFibroGen, Inc2018-05-01Phase 3NCT02988973A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia
ICLRICON plc2018-05-01Phase 3NCT02065882Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency
KMPHKemPharm, Inc.2018-05-01Phase 3NCT03292952KP415 Classroom Study in Children (6-12 Years of Age) With ADHD
PRAHPRA Health Sciences, Inc.2018-05-01Phase 3NCT02552212Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS
SHPGShire plc2018-05-01Phase 3NCT02998554Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Placebo
SHPGShire plc2018-05-01Phase 3NCT02998541Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Povidone-iodine (PVP-I) and Placebo
SHPGShire plc2018-05-01Phase 3NCT02093663Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis
SHPGShire plc2018-05-01Phase 3NCT02895945BAX 802 in CHA With Inhibitors
SUPNSupernus Pharmaceuticals, Inc.2018-05-01Phase 3NCT02618434Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)
TSROTESARO, Inc.2018-05-01Phase 3NCT01905592A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients